Biocon Launches U.S. Breast Cancer Drug Abraxane in India
This article was originally published in PharmAsia News
Executive Summary
India's Biocon began marketing Abraxane (paclitaxel) in the country for treating breast cancer. Biocon licensed the drug last year from Abraxis BioSciences of the United States. The drug already is approved in 35 countries, but Biocon seeks to feed a growing need for the drug in India. The licensing agreement also covers more than 10 other countries in Asia where regulatory approval is sought, including Pakistan and Sri Lanka. (Click here for more
You may also be interested in...
Is Natco's Albupax Equivalent To Abraxis' Cancer Drug Abraxane? India's Drug Controller Probes
MUMBAI - The Drug Controller General of India has launched an investigation to determine if Natco Pharma's generic breast cancer drug Albupax is therapeutically equivalent to Abraxis BioScience's original brand Abraxane. Natco's generic drug was given marketing approval last year September while Indian biotechnology company Biocon is marketing Abraxane in India following an agreement announced in July of last year
India’s Dr. Reddy’s, Natco Strike Deal To Target Abraxane And Several Other Oncology Drugs
MUMBAI - Highly profitable generic drugs - mainly in the oncology segment - are the latest targets for Indian pharmaceutical companies as margins rapidly shrink on commoditized off-patent drugs in the U.S. and several other markets. With that objective, India's Dr. Reddy's Labs and Natco, a company specializing in oncology drugs have signed a deal for the development, manufacture and supply of a basket of value added generic oncology drugs
Abraxis BioScience Gets SFDA Nod For Metastatic Breast Cancer Drug In China
SHANGHAI - Abraxis BioScience received approval from China's State FDA to market its metastatic breast cancer drugAbraxane (paclitaxel albumin-bound particles for injectable suspension) in China, the company announced July 14